Practical Dosing Considerations for Venetoclax

With FDA-approved indications for both chronic lymphocytic leukemia and acute myeloid leukemia, and continued investigation within multiple disease states, venetoclax has become an exciting oral targeted therapy among oncologists.  

Source: CancerNetwork - September 20, 2019 Category: Cancer & Oncology Authors: Kelly Valla, PharmD, BCOP Source Type: news